Nasal cytokine and chemokine responses in experimental influenza A virus infection: Results of a placebo-controlled trial of intravenous zanamivir treatment

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 586-593

  Fritz, R Scott ^a   Hayden, Frederick G ^d   Calfee, David P ^d   Cass, Lindsey M R ^e   Peng, Amy W ^e   Alvord, W Gregory ^b   Strober, Warren ^c   Straus, Stephen E ^c,f  

^a SAIC FREDERICK INC   (United States)

^b Data Management Services Inc   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; VIRUS SIALIDASE; ZANAMIVIR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HUMAN; INFLUENZA VIRUS A; INTRAVENOUS DRUG ADMINISTRATION; MALE; NOSE MUCUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION;

ANTIVIRAL AGENTS; BODY TEMPERATURE; CHEMOKINES; CYTOKINES; DOUBLE-BLIND METHOD; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INJECTIONS, INTRAVENOUS; MALE; NASAL LAVAGE FLUID; NEURAMINIDASE; PLACEBOS; PYRANS; SIALIC ACIDS; TIME FACTORS; ZANAMIVIR;

EID: 0032873656     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314938     Document Type: Article

References (27)

1. 1. Hayden FG, Fritz RS, Lobo MC, Alvord WG, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. J Clin Invest 1998;101:643-9.
2. 2. Hayden FG, Tunkel AR, Treanor JJ, Betts RF, Allerheiligen S, Harris J. Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob Agents Chemother 1994;38:1178-81.
3. 3. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996;275:295-9.
4. 4. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Study Group. N Engl J Med 1997;337:874-80.
5. 5. Hayden FG, Gwaltney JM. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother 1982;21:892-7.
6. 6. Graham MB, Dalton DK, Giltinan D, Braciale VL, Stewart TA, Braciale TJ. Response to influenza infection in mice with a targeted disruption of the interferon γ gene. J Exp Med 1993;178:1725-32.
7. 7. Freidland JS. Chemokines in viral disease. Res Virol 1996;147:131-8.
8. 8. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 1994;55:97-179.
9. 9. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
10. 10. Asensio VC, Campbell IL. Chemokine gene expression in the brains of mice with lymphocytic choriomeningitis. J Virol 1997;71:7832-40.
11. 11. McColl SR, Roberge CJ, Larochelle B, Gosselin J. EBV induces the production and release of IL-8 and macrophage inflammatory protein-1α in human neutrophils. J Immunol 1997;159:6164-8.
12. 12. Olszewsha-Pazdrak B, Casola A, Saito T, et al. Cell-specific expression of RANTES, MCP-I, and MIP-1α by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J Virol 1998;72: 4756-64.
13. 13 Bernasconi S, Cinque P, Peri G, et al. Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. J Infect Dis 1996;174:1098-101.
14. 14. Cook DN, Beck MA, Coffman TM, et al. Requirement of MIP-1α for an inflammatory response to viral infection. Science 1995;269;1583-5.
15. 15. Tumpey TM, Cheng H, Cook DN, Smithies O, Oakes JE, Lausch RN. Absence of macrophage inflammatory protein 1α prevents the development of blinding herpes stromal keratitis. J Virol 1998;72:3705-10.
16. 16. Sprenger H, Meyer RG, Kaufmann A, Bussfeld D, Rischkowsky E, Gemsa D. Selective induction of monocyte and not neutrophil-attracting chemokines after influenza A virus infection. J Exp Med 1996;184:1191-6.
17. 17. Damon I, Murphy PM, Moss B. Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proc Natl Acad Sci USA 1998;95:6403-7.
18. 18. Kledal TN, Rosenkilde MM, Coulin F, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma associated herpesvirus. Science 1997;227:1656-9.
19. 19. Lalani AS, McFadden G. Secreted poxvirus chemokine binding proteins. J Leukoc Biol 1997;62:570-6.
20. 20. Krathwohl MD, Hromas R, Brown DR, Broxmeyer HE, Fife KH. Functional characterization of the C-C chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2. Proc Natl Acad Sci USA 1997;94: 9875-80.
21. 21. Kurihara T, Warr G, Loy J, Bravo R. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med 1997;186:1757-62.
22. 22. Boring L, Gosling J, Chensue SW, et al. Impaired monocyte migration and reduced type I (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997;100:2552-61.
23. 23. Lu B, Rutledge BJ, Gu L, et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1 deficient mice. J Exp Med 1998;187:601-8.
24. 24. Lukacs NW, Chensue SW, Karpus WJ, et al. C-C chemokines differentially alter interleukin-4 production from lymphocytes. Am J Pathol 1997;150: 1861-8.
25. 25. Matsukura S, Kokubu F, Noda H, Tokunaga H, Adachi M. Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A. J Allergy Clin Immunol 1996;98:1080-7.
26. 26. Von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-23.
27. 27. Holzer CT, Von Itztein M, Jin B, Pegg MS, Stewart WP, Wu WY. Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3 didehydro-N-acetylneuraminic acid modified at the C-4 position. Glycoconj J 1993;10:40-4.